Longitudinal change in neurocognitive functioning in children and adolescents at clinical high risk for psychosis: a systematic review
2023

Neurocognitive Changes in Children and Adolescents at Risk for Psychosis

Sample size: 215 publication 10 minutes Evidence: moderate

Author Information

Author(s): Borja Pedruzo, Claudia Aymerich, Malein Pacho, Jon Herrero, María Laborda, Marta Bordenave, Anthony J. Giuliano, Robert A. McCutcheon, Luis Gutiérrez-Rojas, Philip McGuire, William S. Stone, Paolo Fusar-Poli, Miguel Ángel González-Torres, Ana Catalan

Primary Institution: Department of Psychiatry, Basurto University Hospital, Bilbao, Spain

Hypothesis

How does neurocognitive functioning change over time in children and adolescents at clinical high risk for psychosis?

Conclusion

Children and adolescents at clinical high risk for psychosis show worse neurocognitive performance compared to healthy controls, and these impairments may remain stable before and during the transition to psychosis.

Supporting Evidence

  • CHR-P individuals had worse outcomes in verbal learning, sustained attention, and executive functioning compared to healthy controls.
  • Individuals taking antidepressants showed better outcomes in verbal learning than those taking antipsychotics.
  • Neurocognitive impairments may be present before the onset of psychosis and remain stable during the transition.

Takeaway

Kids and teens who might get psychosis have trouble with thinking and learning, and this doesn't get worse as they get closer to having psychosis.

Methodology

A systematic review was conducted to analyze longitudinal changes in neurocognitive functioning in children and adolescents at clinical high risk for psychosis, comparing them to healthy controls.

Potential Biases

Potential biases may arise from the limited number of studies and the exclusion of certain subgroups, such as those with brief limited intermittent psychotic symptoms.

Limitations

The review was limited by the small number of studies that met the inclusion criteria, which affects the generalizability of the findings.

Participant Demographics

The studies included 151 CHR-P patients with a mean age of 16.48 years (32.45% female) and 64 healthy controls with a mean age of 16.79 years (42.18% female).

Statistical Information

P-Value

0.027

Confidence Interval

95% CI 0.19–0.21

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1007/s00787-023-02221-9

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication